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Abstract
Background: The cell type, cell status and specific localization of Prothymosin α (PTMA) within cells seemingly
determine its function. PTMA undergoes 2 types of protease proteolytic modifications that are useful in elucidating
its interactions with other molecules; a factor that typifies its roles. Preferably a nuclear protein, PTMA has been
shown to function in the cytoplasm and extracellularly with much evidence leaning on pathognomonic status. As
such, determination of its cellular distribution under normal physiological context while utilizing varied techniques
is key to illuminating prospective validation of its distinct functions in different tissues. Differential distribution
insights at normal physiology would also portent better basis for further clarification of its interactions and proteolytic
modifications under pathological conditions like numerous cancer, ischemic stroke and immunomodulation. We
therefore raised an antibody against the C terminal of PTMA to use in tandem with available antibody against the N
terminal in a murine model to explicate the differences in its distribution in brain cell types and major peripheral
organs through western blotting and immunohistochemical approaches.
Results: The newly generated antibody was applied against the N-terminal antibody to distinguish truncated versions
of PTMA or deduce possible masking of the protein by other interacting molecules. Western blot analysis indicated
presence of a truncated form of the protein only in the thymus, while immunohistochemical analysis showed that in
brain hippocampus the full-length PTMA was stained prominently in the nucleus whereas in the stomach full-length
PTMA staining was not observed in the nucleus but in the cytoplasm.
Conclusion: Truncated PTMA could not be detected by western blotting when both antibodies were applied in all
tissues examined except the thymus. However, immunohistochemistry revealed differential staining by these
antibodies suggesting possible masking of epitopes by interacting molecules. The differential localization
patterns observed in the context of nucleic versus cytoplasmic presence as well as punctate versus diffuse
pattern in tissues and cell types, warrant further investigations as to the forms of PTMA interacting partners.
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Background
Prothymosin α (PTMA) is an unstructured, extremely
acidic protein (pI 3.5), expressed in a wide variety of cell
types. Progressively, research has attested to it as a protein
of clinical significance and potential medical use [1, 2]. It
is considered a nuclear protein with a potent nuclear
localization signal (NLS), albeit reports indicate cytoplas-
mic and extracellular presence as well, under specific
physiological or pathological conditions [3, 4]. It has a
highly conserved amino acid sequence among mammals
and this together with its wide distribution affirm that it
plays an essential role in an organism other than the trad-
itionally attributed role of immune modulation.
Even so, the precise function is still not well understood.
Accumulating data point towards both intracellular and
extracellular biological functions of PTMA [5–11]. The
major intracellular role is associated with cell proliferation.
It has been reported that PTMA stimulates cell prolifera-
tion by sequestering a repressor of estrogen receptor activ-
ity in various cells [12]. Cancer cells are known to be
highly proliferative and indeed high expression of intracel-
lular PTMA has been correlated with progression of a
number of cancer types including bladder cancer, liver
cancer, breast cancer, head and neck cancer, lung cancer,
colon cancer, rectal cancer, ovarian cancer, neuroblastoma,
prostate cancer and gastric cancer [13–26]. Moreover,
PTMA binds to histones, p300 histone acetyl transferase
and cAMP response element binding protein (CREB)-
binding protein to induce gene transcription [27, 28]. Re-
cent studies have explored the role of intracellular PTMA
in acetylation regulation [29].
Further intracellular roles of PTMA include its in-
volvement in cell survival. Nuclear Factor erythroid 2 re-
lated factor (Nrf2), a transcription factor that regulates
expression of defensive genes such as antioxidant pro-
teins and detoxifying enzymes, is inhibited by Kelch-like
ECH-associated protein 1(Keap1). On one hand, PTMA
binds to Keap1 to dissociate Keap1-Nrf2 complex thus
upregulating the expression of Nrf2 dependent anti-
oxidative stress genes [30]. On the other hand, it has
been reported in mediating nuclear import of Keap1 to
degrade nuclear Nrf2 and thus switch off downstream
gene expression suggesting that it is involved in on/off
switch of Keap1-Nrf2 system [31]. Moreover, PTMA acts
as an anti-apoptotic molecule in the cytoplasm by inter-
acting with Apaf1 to inhibit apoptosome formation [32]
and by binding to cytochrome c [33] thereby inhibiting
caspase activation. Reports also show that it interacts
with p8 (nuclear protein 1), a natively unstructured pro-
tein with anti-apoptotic activity much like PTMA, to
form a heterodimer complex that could act in concert to
regulate the apoptotic cascade [34]. Interestingly how-
ever, PTMA undergoes caspase mediated fragmentation
in apoptotic cells at two amino-terminal sub-optimal
sites and one carboxy-terminal optimal site [35, 36].
Cleavage at the latter site disrupts its nuclear localization
and subsequently its intranuclear functioning [37].
Extracellularly, PTMA plays a role in immunomodula-
tion via a pleiotropic mode by stimulating a variety of
immune cells including natural killer cells, T cells and
lymphokine-activated killer cells-dendritic cells, mono-
cytes and macrophages. The mechanism by which it reg-
ulates immune responses is proposed to be through
binding to TLR4 on innate immune cells to trigger in-
duction of pro-inflammatory cytokines. Reports also
show that the C-terminus of PTMA holds the immuno-
logically active site of the polypeptide [38]. Seemingly,
different parts of the molecule are responsible for the
different biological functions it exerts.
Reports from our laboratory also show that extracellu-
lar PTMA can confer protection to neurons upon ische-
mic stress by inhibiting necrosis [39]. Cell death that
occurs as a consequence of obstructed blood flow in a
brain region causes damage to tissues and results in is-
chemic stroke. Two modes of cell death occur during is-
chemic stroke: necrosis at the ischemic core and
apoptosis several days later at the region that surrounds
the core called the penumbra. Necrosis, a rapid and
expanding process contributes largely to cell damage but
to this end there are no known inhibitors of necrosis.
Apoptosis on the other hand can be inhibited by growth
factors. Importantly, PTMA was identified as a molecule
that can initiate a switch from uncontrollable necrosis to
tractable apoptosis in ischemic neurons [40]. Further
findings on the neuroprotective role of PTMA revealed
neuron-specific extracellular release of the polypeptide
following ischemic stress. PTMA was released in a non-
classical manner and this release was mediated by its
interaction with the cargo protein, S100A13 [41]. The
interaction was shown to require the C-terminal region
of PTMA. Since astrocytes have intrinsic caspase 3 activ-
ity it was postulated that the non-release of PTMA in
astrocytes in brain following ischemia was as a result of
caspase cleavage of PTMA in its C-terminus thus de-
priving it the interaction with S100A13. In addition, cas-
pase cleavage of PTMA disrupts its nuclear localization,
resulting in redistribution of the polypeptide. PTMA is
also capable of proteolytic lysis by asparaginyl endopep-
tidase in its N-terminus to yield thymosin alpha 1 (TA1)
but it still remains to be elucidated if this proteolysis is
simply a step in the catabolism of PTMA or a more spe-
cific selective process in view of some biological function
of TA1 [42].
Depending on the proteins which it interacts with,
PTMA exerts different effects; a feature that is deter-
mined by its subcellular localization. To individualize
PTMA interactions and proteolytic modifications that
occur in different tissues, it is a prerequisite to
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determine its cellular modelling in diverse tissues. The
subcellular localization in tissues under normal physio-
logical context has been under reported yet this is a core
basis for further elucidation of its interactions and pro-
teolytic modifications under pathological conditions like
the various cancer forms, ischemic stroke and immuno-
modulation mechanisms where it exhibits extensively
contrasting roles depending on the pathognomonic sta-
tus and localization. In the present study, we implore
western blotting and immunohistochemical techniques
to explore the expression of PTMA and its specific cel-
lular localization in different murine tissues using a set
of monoclonal antibodies raised against different epi-
topes on the polypeptide; the brain being the predomin-
ant organ of investigation based on our earlier findings
[39–41]. First, we generated a monoclonal antibody
against the C-terminal region of PTMA (AntiCT) and
employed it in conjunction with the anti N-terminal
monoclonal antibody (2 F11) for a comparison. We
therefore observe that, the preferential combination of
the applied techniques and monoclonal antibodies would
lay ground to prospective examinations for better under-
standing of factors that mediate biological function of
PTMA across brain cells and other peripheral tissues
not only during proteolytic modifications in pathological
conditions but also under normal physiology context.
Methods
Experimental animals
Two female Wistar rats were used for the generation of
monoclonal antibodies. Male MP-BL mice were used for
the western blotting and immunohistochemistry experi-
ments. The animals were kept in a room maintained at
constant temperature (21 ± 2 °C) and relative humidity
(55 ± 5 %) with an automatic 12 h light/dark cycle with
free access to standard laboratory diet and water ad
libitum.
Immunization of animals
Synthetic biotinylated carboxy-terminal peptide of
PTMA, (bearing the sequence DDVDTKKQKTEEDD,
-Cat.No 293211. GL Biochem Shanghai Ltd), was used
as immunogen. Wistar rats were anesthetized and im-
munized with 200 μg avidin conjugated immunogen,
injected on the foot pads as emulsions (1:1 v/v) in
complete Freund’s adjuvant (Cat No. 263810, DIFCO La-
boratories Detroit, MI) Blood was collected from the im-
munized animals 2 weeks after the injection and the
serum tested for immune reactivity with recombinant
mouse PTMA. A week later the animals were sacrificed
and the medial iliac lymph nodes aseptically harvested
as previously reported [43, 44].
Characterization of the antibody
Hybridomas were prepared using the isolated medial
iliac lymph node cells and SP2/0 myeloma cells as the
fusion partner in the presence of polyethylene glycol
(PEG) and cultured in Hypoxthanthine Aminopterin
Thymidine (HAT) selective medium. Cell culture media
was then assayed by standard Enzyme linked Immuno-
sorbent Assay (ELISA) for the presence of PTMA-
reactive antibodies and cells from the ELISA-positive
wells cloned by limiting dilution. Screening of hybrid-
oma cell line supernatants was performed via ELISA.
Positively identified hybridoma clones were expanded
and inspected for monoclonality then assayed by ELISA
for immune-reactivity. Desired clones were subsequently
re-expanded and adapted to RPMI1640 medium. The
monoclonal antibody was then purified from the super-
natant by Protein G affinity chromatography and the
concentration of purified antibody was determined by
Lowry method.
Application of antibody in western blot analysis
Mice were decapitated and the desired brain regions
(Olfactory bulb, cortex, amygdala, hippocampus, stri-
atum, cerebellum, thalamus, hypothalamus, mid brain
pons and medulla) and tissues (peripheral tissues includ-
ing spleen, thymus, lung, heart, kidney, liver, colon,
stomach, duodenum, jejunum, ileum and cecum) were
obtained and transferred into ice-cold homogenizing
buffer (20 mM Tris-HCI, pH 7.4, 10 mM NaCl, 1 mM
EDTA, 0.01 % SDS, 1 % Triton X-100 and 1X protease
inhibitor cocktail) . Tissue lysis was performed using tis-
sue homogenizer or sonication. The homogenate was
centrifuged at 15,000 rpm for 30 min at 4 °C. An aliquot
of the supernatant was taken for protein quantification,
equivalent amounts of total protein mixed with 2 x SDS
sample buffer and heated in a boiling water bath for
5 min. The boiled samples were either used immediately
or frozen at –20 °C.
Protein quantification of recombinant PTMA and total
protein concentration of tissue homogenates was deter-
mined by Lowry protein assay method. Samples were
prepared for loading onto gel using 1×SDS loading buffer
as previously described. Indicated quantities of recom-
binant Prothymosin α and the tissue samples containing
20 μg of total protein were electrophoresed on 15 %
SDS-polyacrylamide gels, transferred onto a nitrocellu-
lose membrane by electroblotting performed at 30 V,
100 mA for 90 min and subjected to immunoblotting
with appropriate antibody. In the case of untagged re-
combinant and tissue PTMA, transfer onto a membrane
was by electroblotting with acidic buffer (20 mM sodium
acetate buffer, pH 5.2) followed by fixation with 0.5 %
glutaraldehyde. Blotted membranes were blocked with
5 % skim milk and 2 % FBS in TBST or 5 % BSA.
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Membranes were then probed with rat/mouse anti-
PTMA (AntiCT and 2 F11 from Alexis Biochemicals
respectively) and mouse anti-GAPDH (internal control)
primary antibodies followed by Horseradish Peroxidase
(HRP)-conjugated goat secondary antibodies. Visualization
of immunoreactive bands was executed by enhanced
chemiluminescent (ECL). Densitometry of the detected
protein bands was determined using ImageJ software. The
densitometry ratio of PTMA to GAPDH was calculated.
For the purpose of comparison between tissues and be-
tween different sets of experiments, the densitometry ratio
of each tissue was plotted.
Application of antibody in immunoprecipitation assay
10 μg Protein G sepharose fast flow slurry was incubated
with 10 μg of indicated antibody at 4 °C overnight in agi-
tating condition. The beads were then washed 3 times
each with wash buffer and incubated with sample (tissue
lysate or recombinant protein), at 4 °C for 4 h followed
by 3 washes and eluted with 1X SDS loading buffer.
Immunoprecipitated samples were then boiled for 5 min
and analysed by western blot.
Application of antibody to immunohistochemistry
Mice peripheral tissues and specific brain regions were
fixed by vascular perfusion with 30 mL of 4 % parafor-
maldehyde (PFA) after perfusion with PBS for about
20 min. Desired organs were isolated and washed with
PBS then processed using a rapid microwave automatic
histo-processor using a standard protocol and embedded
into paraffin wax. Subsequent immunohistochemistry
assays were then performed per standard protocols pre-
viously described [15]. Briefly, sectioned tissues were
deparrafinized then permeabilized with methanol. The
sections were then blocked with 3 % BSA for 1 h at
room temperature and later incubated with primary
antibody (1:300 mouse monoclonal IgG 2 F11; Enzo Life
Sciences Int., PA, USA and AntiCT)) at 4 °C overnight,
washed with PBST then with secondary antibody conju-
gated to AlexFluor (1:600) for 2 h at room temperature.
Counterstaining with Hoechst 33342 (1:10,000) was
effected. The slides were then mounted by pristine
mount and left to dry overnight at 4 °C. Images were
collected by BZ-8000 microscope (KEYENCE, Osaka,
Japan) with a × 20 Plan APO lens (Nikon, Tokyo, Japan).
Application of antibody to immunocytochemistry
Primary cortical cells on an eight-well Lab Tek chamber
were fixed in 4 % PFA in PBS at 4 °C overnight followed
by 3 wash steps with PBS. Fixed cells were permeabilized
with 50 and 100 % methanol for 10 min each then
washed with PBS 3 times. The permeabilized cells were
washed with 0.1 % Triton X-100 in PBS (PBST), incu-
bated in blocking buffer (3 % BSA in PBST) for 3 h at
4 °C, and then incubated in primary antibody (1 : 300;
mouse monoclonal IgG 2 F11; Enzo Life Sciences Int.,
PA, USA and AntiCT) overnight at 4 °C. The cells were
then washed with PBST and thereafter incubated in a
secondary antibody conjugated to AlexFluor. The nuclei
were visualized with Hoechst 33342. Images were col-
lected using a BZ-8000 microscope (KEYENCE, Osaka,
Japan) with a × 20 Plan APO lens (Nikon, Tokyo, Japan).
Ethical clearance
All the procedures were formally approved by Nagasaki
University Animal Care Committee. The guidelines were
strictly adhered to during the research.
Results
Selection of hybridoma cell lines secreting monoclonal
antibodies by indirect ELISA was performed using puri-
fied Glutathione S- transferase (GST) and Maltose bind-
ing protein (MBP) tagged recombinant PTMA as the
antigen. From approximately 1500 primary hybridomas
16 yielded immune reactive signals 3-100-fold above
background as indicated by optical density (OD) values
(data not shown). The 16 hybridomas were all confirmed
to react with recombinant PTMA in a second round of
ELISA screening. To determine whether the secreted
antibodies could specifically detect full-length PTMA,
the 16 hybridoma candidates were tested for their re-
activity against recombinant mouse PTMA by western
blot analysis (Fig. 1). The C-terminal truncated PTMA
was included to assay the specific detection of C-
terminus region. Supernatant from the hybridoma cell
culture was used for the analysis. The antibodies from
the cultures could detect full-length PTMA but not the
C-terminal truncated one.
To further investigate if the generated antibody could
detect rat and human PTMA, western blot analysis was
carried out using purified recombinant full-length
mouse, rat and human Prothymosin α (Fig. 2). Super-
natant from the hybridoma culture was used for this
analysis. Clones 1, 5 and 7 showed somewhat similar sig-
nal intensities for the detection of PTMA across the spe-
cies. On the other hand, clones 3, 4, 8, 13, 15 and 16
showed higher affinity for mouse PTMA whereas clones
9, 11 and 12 lost their ability to secret the antibodies.
Clones 10 and 14 showed relatively very weak signal in-
tensities. PTMA sequence is highly conserved across
species (Fig. 3), coloured amino acids denote less con-
served sections. While amino termini of all three species
show precise homology, the carboxy termini show some
differences between the species. Nevertheless, some anti-
bodies from various hybridoma cell lines could recognize
the c-terminus of PTMA across species.
Clone 7 (Figs. 1 and 2) was selected for further culture
due to its consistency in PTMA detection after cloning.
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The selected clone was adapted to RPMI1640 medium
and antibody immunoreactivity confirmed. The hybro-
doma clone was then grown in serum free GIT medium
and the secreted antibodies were purified by protein G
affinity chromatography, dialyzed with PBS and later
antibody concentration was determined. Reactivity of
the purified antibody was assayed by western blotting
and antibody tested for capacity to immunoprecipitate
PTMA from tissue and the recombinant PTMA. AntiCT
antibody successfully immunoprecipitated PTMA from
the cerebellum tissue lysate. Anti N-terminal PTMA
(2 F11) was applied alongside AntiCT in the immuno-
precipitation studies for a comparison. Detection of
PTMA immunoprecipitated by both antibodies was car-
ried out by 2 F11. Same amount of antibody was used
for each antibody type. 2 F11 antibody showed greater
capacity for immunoprecipitation than AntiCT.
The tissue-wide distribution of PTMA was assessed
using the newly generated anti C-terminal PTMA
(AntiCT) and the anti N-terminal PTMA (2 F11)
Fig. 1 Western blot analysis of hybridoma immune-reactivity MBP and GST tagged recombinant mouse PTMA (as shown in the inlet) were loaded
onto gel for electrophoresis and thereafter blotted on to nitrocellulose membranes. Blotted membranes were incubated with supernatant from
the hybridoma cultures from different clones as indicated. HRP conjugated anti-rat IgG secondary antibody and HRP substrate was used to develop
the bands. Signals were detected by enhanced chemiluminescence. No band was detected on the C-terminal deleted mutant of PTMA (lane 3), while
bands corresponding to full-length tagged recombinant PTMA were detected with different intensities across the clones
Fig. 2 Determination of cross reactivity of the antibodies with rat and human PTMA. GST tagged recombinant mouse, rat and human PTMA were
loaded onto gel for electrophoresis and blotted on to nitrocellulose membranes thereafter. Blotted membranes were incubated with supernatant
from the hybridoma cultures from different clones as indicated. Antibodies from most clones showed crossreactivity with rat and human PTMA.
Some showed relatively similar or different signal intensities indicative of the affinity of the antibodies to the particular antigens. Clones 9, 11 and
12 lost their ability to secret antibodies
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antibodies. To explore whether proteolytically modified
forms of PTMA could be detected by the set of anti-
bodies, the immunoblot assay was performed in brain
regions and peripheral tissues. Immunoblot data re-
vealed a single band detectable by both 2 F11 and
AntiCT that corresponded to full-length PTMA in the
brain regions (Fig. 4), no additional bands were detected
indicative of proteolytic modification of PTMA. In per-
ipheral tissues, a similar observation was made (Fig. 5),
however an additional lower band was detectable by
2 F11 only in the thymus suggesting c-terminal trun-
cated version o or several different variants of PTMA
could be present. The relative levels of PTMA in differ-
ent tissues were calculated according to densitometry
measurements and the data are summarized. Densito-
metric quantification of the western blot bands of
PTMA expression across peripheral tissues and selected
brain regions [Additional files 1 and 2 correspondingly]
corresponding to Figs. 4 and 5 respectively. In the brain,
the highest levels of PTMA were detected in the olfac-
tory bulb and cerebellum by both antibodies while in
peripheral tissues, the thymus, spleen and lungs showed
high PTMA levels by both antibodies. Relatively low
PTMA levels were detected in the heart, kidney and
liver.
PTMA localization was evaluated by immuno-
histochemistry in a spectrum of organs Multi-colour
experiment was performed for PTMA visualization by
co-staining with AntiCT and 2 F11 antibodies. Hoechst
stain was used to visualize the nucleus. We observed a
differential staining pattern among the tissues examined.
Immunoreactivity of PTMA was mainly in the nucleus
of most tissues, while other tissues indicated predomin-
ant cytoplasmic staining. In the hippocampus PTMA
signals were intense in the nucleus (Fig. 6a iii) when de-
tected by both Anti CT and 2 F11 (Fig. 6a i and ii)
clearly indicated by the merge data (Fig. 6a iv). In the
lungs, an intriguing observation was made in the pattern
of distribution of PTMA expression. The AntiCT anti-
body stained both nucleus and cytoplasm (Fig. 6b i iii
and iv) in majority of the cells while 2 F11 stained only
the cytoplasm in most cells and the perinuclear space in
few cells (Fig. 6b ii, iii and iv).
The heart presented weak PTMA immunostaining by
both AntiCT and 2 F11 antibodies (Fig. 7a i, ii and iii)
and clearly illustrated by the merge (Fig. 7a iv) in correl-
ation with the western blot data that indicated weak
PTMA expression. In the kidney, PTMA was primarily
expressed in the nucleus (Fig. 7b iii) by both antibodies
(Fig. 7b i and ii) with AntiCT showing more intense
signal (Fig. 7b iv).
In the liver PTMA was demonstrated considerably in
the nucleus (Fig. 8b iii) by both AntiCT ant 2 F11 (Fig. 8a
i, ii and iv), this correlates with the western blot data
that showed substantial expression of PTMA. In the
stomach, PTMA immunoreactive cells of the mucosal
Fig. 3 Alignment of amino acid sequences of human, rat and mouse Prothymosin alpha
Fig. 4 Western blot analysis of the distribution of PTMA in selected brain regions. Immunoreactive PTMA from regions of the brain tissue shows single
bands at apparent molecular weight of 12 kDa. Lysates from multiple sections of the brain were resolved in electrophoretic gel and transferred to
nitrocellulose membranes. The western blot analysis was performed with monoclonal 2 F11 and monoclonal AntiCT. Untagged recombinant PTMA
was used as positive control and GAPDH as internal control
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layer demonstrated quite a unique distribution pattern.
PTMA was not stained in the nucleus (Fig. 8b iii) of
these cells by either of 2 F11 or AntiCT antibodies
(Fig. 8b i and ii). Interestingly, only the cytoplasm was
positively immunostained, clearly indicated by the merge
data (Fig. 8b iv). Showing both antibodies exhibited
strong cytoplasmic immunofluorescent intensity.
The duodenum showed PTMA immunoreactivity in
the nucleus (Fig. 9a iii) and weakly in the cytoplasm but
AntiCT (Fig. 9a i) demonstrated higher signal intensity
than 2 F11 (Fig. 9a ii). Additionally, 2 F11 depicted peri-
nuclear staining in some submucosal layer cells. The je-
junum also presented an exceptional PTMA staining
pattern in which the AntiCT shows immunoreactivity
mainly in the nucleus (Fig. 9b i and iii) while 2 F11 de-
picts mainly a cytoplasmic immunostaining (Fig. 9b ii).
Some cells show perinuclear staining with 2 F11 only,
while few show perinuclear staining with both antibodies
(Merge, Fig. 9b iv).
Ileum, colon and cecum demonstrated a similar pat-
tern of distribution of immunoreactive PTMA (Figs. 10a, b
and 11 respectively). The AntiCT stained with much higher
fluorescent intensity (Figs. 10a i, iii; b i, iii and Fig. 11 i, iii),
depicting strong nucleus signal compared to cytoplasmic
signal. 2 F11 showed moderate nucleus signal (Figs. 10a ii,
iii; b ii, iii and Fig. 11 ii, iii). An overlay of PTMA
and nuclear staining is shown in the merge data
(Figs. 10a, b and 11iv).
Given that PTMA has previously been shown by 2 F11
to be exclusively located in the nuclei of neurons we ex-
plored cell-type specific distribution of PTMA: an im-
munocytochemical study, by immunostaining with newly
generated anti C-terminus PTMA antibody whether a
similar staining pattern would be observed. We used
Fig. 5 Western blot analysis of the distribution of PTMA across peripheral tissues. Immunoreactive PTMA from various peripheral tissues shows single
bands at apparent molecular weight of 12 kDa. Lysates from the peripheral tissues were resolved in electrophoretic gel and transferred to nitrocellulose
















b (Lung tissue PTMA analysis)
Fig. 6 Immunohistochemistry analysis of PTMA in (a) mouse brain hippocampus tissue and (b) Lung tissue. Whole animal vascular perfusion
fixation was conducted with PFA and the required tissues were isolated. The brain hippocampus and lung were processed for immunohistochemistry
by embedding to paraffin wax. Tissue sections were stained with AntiCT (a)i and (b)i and 2 F11 (a)ii and (b)ii together with relevant fluorescent tagged
antibodies. Sections were then washed, counterstained with Hoechst (a)iii and (b)iii and processed for fluorescence microscopy. Both antibodies
localized PTMA in the nucleus of the hippocampus (a)i and ii, while in the lung PTMA immunoreactivity was observed in the nucleus and cytoplasm
by AntiCT (b)i but mainly in the cytoplasm by 2 F11 (b)ii
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primary cortical neurons cultured from 17 day-old em-
bryonic rat brain. Anti C-terminal PTMA depicted a
punctate signal that was widely distributed throughout
the nucleus; weak signals were also detected in the cyto-
plasm as by the arrow heads shown (Fig. 12), eliciting
contrast with the 2 F11 antibody.
Discussion
Prothymosin α (PTMA) generates a great deal of interest
among investigators due to its robust involvement in a
variety of biological processes ranging from cell prolifer-
ation as observed in several types of cancer [13–26] and


















b (PTMA examination in kidney tissue)
Fig. 7 Immunohistochemical examination of PTMA in (a) mouse heart and (b) kidney tissue. Whole animal vascular perfusion fixation was conducted
with PFA and the required tissues were isolated. The heart and kidney were processed for immunohistochemistry by embedding to paraffin wax.
Tissue sections were stained with AntiCT (a)i and (b)i and 2 F11(a)ii and(b)ii together with relevant fluorescent tagged antibodies. Sections were then
washed, counterstained with Hoechst (a)iii and(b)iii) and processed for fluorescence microscopy. The heart PTMA immunoreactivity was moderate by


















b (PTMA profile in the stomach)
Fig. 8 Immunohistochemical examination of PTMA expression levels in (a) mouse liver tissue and (b) stomach. Whole animal vascular perfusion
fixation was conducted with PFA and the required tissues were isolated. The liver and stomach were processed for immunohistochemistry by
embedding to paraffin wax. Tissue sections were stained with AntiCT (a)i and (b)i and 2 F11 (a)ii and (b)ii together with relevant fluorescent
tagged antibodies. Sections were then washed, counterstained with Hoechst (a)iii and (b)iii and processed for fluorescence microscopy. The liver
shows substantial nucleic PTMA immunoreactivity by both antibodies (a)i and ii whereas only the cytoplasm showed immunofluorescence by
both 2 F11 and AntiCT in the stomach (b)i and ii
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mediated immunity [6, 8, 46]. Moreover, going by recent
studies conducted to understand the role PTMA in non-
mammalian vertebrates, insights into changes in PTMA
functions and expression that have occurred with evolu-
tion is required. It has been shown that PTMA is in-
volved in spermatogenesis in the frog [47, 48] and in the
cartilaginous fish Torpedo marmorata [49]. In the zebra-
fish, the PTMA gene has been shown to be duplicated
[50] and expressed differentially during embryonic devel-
opment indicating that their function is more complex
in fishes than in mammals.
As yet, its subcellular localization in tissues under nor-
mal physiological context has been underreported
equally utilizing narrow range techniques. In the present
study we demonstrated the tissue distribution and sub-
















b (Analysis of PTMA in Jejunum)
Fig. 9 Immunohistochemical analysis of PTMA in (a) mouse duodenum and (b) Jejunum. Whole animal vascular perfusion fixation was conducted
with PFA and the required tissues were isolated. The duodenum and jejunum were processed for immunohistochemistry by embedding to paraffin
wax. Tissue sections were stained with AntiCT (a)i and (b)i and 2 F11 (a)ii and (b)ii together with relevant fluorescent tagged antibodies. Sections were
then washed, counterstained with Hoechst (a)iii and (b)iii) and processed for fluorescence microscopy. In the duodenum, PTMA immunoreactivity
















b (Manifestation of PTMA in colon tissue)
i iii
ii iv
Fig. 10 Immuohistochemical analysis of PTMA in (a) mouse ileum tissue and (b) colon. Whole animal vascular perfusion fixation was conducted
with PFA and the required tissues were isolated. The ileum and colon were processed for immunohistochemistry by embedding to paraffin wax.
Tissue sections were stained with AntiCT (a)i and (b)i and 2 F11 (a)ii and(b)ii together with relevant fluorescent tagged antibodies. Sections were
then washed, counterstained with Hoechst (a)iii and(b)iii and processed for fluorescence microscopy. The ileum and colon depict nucleic PTMA
staining with AntiCT (a and b)i and cytoplasmic staining with 2 F11 (a and b)ii
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tissues and cell types. The insights into its differential
dissemination in brain cell types and major peripheral
organs at normal physiology, would portent better basis
for further elucidation of its interactions and proteolytic
modifications under pathological conditions. This con-
siders the fact that, it exhibits extensively contrasting
roles depending on the pathognomonic status and
localization as either intracellular or extracellular. To il-
luminate the differential distribution and localization of
PTMA, with respect to different tissues and cell types,
antibodies that discriminate the different epitopes on the
polypeptide were useful tools. First we developed an
antibody against the C-terminus of PTMA, a region that
presents relatively high hydrophilicity and mobility indi-
ces and is therefore likely to have high antigenicity,
according to a previous theoretical evaluation [51]. Add-
itionally, antigenic determinants of polypeptides are
usually located in their N and/or C termini therefore the
C-terminus of PTMA is putatively immunogenic. The
rat iliac lymph node method was utilized to produce the
monoclonal antibodies instead of the conventional
spleen method as it offers a number of benefits; (a) a
single injection is sufficient for immunization, (b) lymph
nodes are ready to use 2 weeks after injection and (c) in-
crease in efficiency (10 times higher than conventional
method) due to higher yield of positive hybridomas. In
this method, biotinylated C-terminal peptide of PTMA
was used as antigen and emulsified with complete
Freund’s adjuvant. Rats were immunized once and
3 weeks later lymphocytes from the iliac lymph nodes of
immunized rats were fused with SP2/0 myeloma cells.
Antibody producing hybridomas were screened by
ELISA and 16 positive clones were selected. On assaying
reactivity of the purified antibody by western blotting
and antibody testing for capacity to immunoprecipitate
PTMA from tissue and the recombinant PTMA, it was
evident that AntiCT antibody successfully immunopreci-
pitated PTMA from the cerebellum tissue lysate. When
Anti N-terminal PTMA (2 F11) was applied alongside
AntiCT for comparison and detection of PTMA immu-
noprecipitated by both antibodies carried out by 2 F11
using same amount of antibody for each antibody type;
2 F11 antibody showed greater capacity for immunopre-
cipitation than AntiCT. It is worth noting that the pres-
ence of variant proteins with the same N-terminal
sequence generated from alternative splicing of the
PTMA gene as recently reported [46] would possibly ac-
count for this difference. This observation needs to be









Fig. 11 Immuohistochemical examination of PTMA in cecum. The
cecum was processed for immunohistochemistry by embedding to
paraffin wax. Tissue sections were stained with AntiCT (i) and 2 F11 (ii)
together with relevant fluorescent tagged antibodies. Sections were
then washed, counterstained with Hoechst (iii) and processed for
fluorescence microscopy. Some cells showed PTMA immunoreactivity
in both nucleus and cytoplasm with both antibodies while others
show nucleus staining with AntiCT and cytoplasmic staining with









Fig. 12 Cellular distribution of PTMA in rat primary neurons. Fixed rat
primary cortical neuron cells were permeabilized with 50 and 100 %
methanol then washed with PBS. The permeabilized cells were
incubated in blocking buffer, and then with AntiCT (a)i and
2 F11(b)ii. Stained cells were then processed for fluorescence
microscopy. C-terminal antibody stained PTMA in the primary
cortical neurons with a punctate pattern while anti N-terminal
showed diffuse nuclear staining. Arrowheads denote the weak
cytoplasmic signals detected by the anti C-terminal PTMA
antibody only
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The applied methodology revealed that the generated
antibody was able to recognize full-length PTMA but
could not detect the C-terminal truncated mutant as
shown by the western blot results therefore, demonstrat-
ing the specificity of the antibodies to the C-terminal re-
gion of PTMA. Further characterization of the antibody
by determining its cross reactivity with rat and human
PTMA revealed clones with different species-specific af-
finities for PTMA while some clones lost the ability to
secrete the antibodies possibly due to loss of chromo-
somes. Taken together, these results indicated successful
generation of the C-terminal antibody. For subsequent
experiments purified antibody from clone 7 (AntiCT)
was used. A previous study by our laboratory showed
that PTMA is a unique cell death regulatory molecule
and therefore has neuroprotective roles in brain stroke
[39, 45]. Additional studies demonstrated that PTMA
exerts the neuroprotective function via its extracellular
release upon interaction with S100A13 and that the C-
terminal region of PTMA is required for this interaction
[41]. However, PTMA cleavage by caspase in its C-
terminus interferes with the interaction with S100A13
and disrupts its nuclear localization. Concurrently,
PTMA undergoes asparaginyl endopeptidase-mediated
cleavage in its N-terminus [42]. Such proteolytic modifi-
cations could present functional discontinuities of
PTMA and aid to unearth other macromolecules that
participate in PTMA functions. Therefore, we first inves-
tigated the presence of proteolytically modified variants
of PTMA in mouse tissues by western blotting. When
AntiCT was applied against 2 F11 in the immunoblot
assay, a differential PTMA distribution pattern was ob-
served in the brain regions and peripheral tissues. The
tendency of PTMA expression pattern was similar by
both antibodies, depicting a trend of high expression
levels in brain regions associated with high neuron
population (cerebellum) and regions in which neurogen-
esis is known to occur (olfactory bulb and hippocam-
pus). Brain regions that showed the lowest levels include
the thalamus and cortex. Only a single band signal was
detectable, cleaved forms of PTMA were undetectable in
brain region. In peripheral tissues PTMA expression was
higher in lymphoid tissues such as thymus and spleen
and lowest in the liver, only the thymus registered an
additional lower band signal when detected by 2 F11
which was undetectable by AntiCT. It is plausible that
this lower molecular weight band is indeed the C-
terminal cleaved form of PTMA owing to the fact that
the thymus is packed with apoptosing cells as a result of
high cell turnover in this tissue. Further experiments will
help to unequivocally determine the identity of the lower
band. Overall, the expression level of cleaved forms of
PTMA was undetectable in all tissues tested except the
thymus under normal physiological context. It would be
interesting to explore this phenomenon after induction
of some stress. Following the revelation of the PTMA
expression trend in the various tissues, we explored the
subcellular localization by use of immunohistochemistry
techniques.
Immunohistochemical analysis was performed by co-
staining with both antibodies (AntiCT and 2 F11). Im-
munostaining with AntiCT revealed that in most of the
tissues analyzed, the expression of PTMA was localized
in both the nucleus and cytoplasm while PTMA immu-
noreactivity was mostly detected in cytoplasm or peri-
nuclear space by 2 F11. Specific cells of the mucosal
layers of duodenum, jejunum, ileum, colon and cecum
corroborated this observation. Some cells in the sub-
mucosal layers of the duodenum and cecum showed
PTMA immunoreactivity in the perinuclear space only
by both antibodies. It is conceivable that this differential
subcellular localization of PTMA is as a result of differ-
ent PTMA interacting molecules in the different tissue
and cell types or proteolytic modification of PTMA,
however no PTMA cleaved forms were detected in these
tissues. The brain hippocampus and stomach tissue sec-
tions revealed interesting staining patterns that differed
from the aforementioned tissues. On one hand, exclusive
nuclear staining of PTMA was observed in the hippo-
campus by both antibodies and on the other hand exclu-
sive cytoplasmic staining was observed in the stomach
when both antibodies were applied. As PTMA plays
multiple cell robustness roles, this specified subcellular
localization in the hippocampus and the stomach by
both AntiCT and 2 F11 suggests cell type specific func-
tioning of PTMA. The expression intensity in other tis-
sues like the liver and the heart was relatively weak
while the kidney showed comparatively higher signal in-
tensity by immunohistochemistry where the signal was
mainly localized in the nucleus. Interestingly the im-
munofluorescence detected in the lung tissues showed
both nucleus and cytoplasmic staining by AntiCT but
only cytoplasmic staining by 2 F11. This could be attrib-
utable to an interacting molecule involving the N-
terminal of PTMA in the nucleus of lung cells. To
determine the pattern of cellular distribution of PTMA
in detail, immunocytochemistry analysis was carried out
on primary neurons. As observed, AntiCT depicted a
punctate distribution pattern in the nucleus of neurons
and weakly stained the cytoplasm, features that differed
from immunostaininng with 2 F11 which only stained
the nucleus diffusely. We could consider the prospect
that the punctate pattern detectable by AntiCT in pri-
mary neurons is a product of interacting molecules in
the nucleus that mask C-terminal region and that the
weak cytoplasmic signal detectable by AntiCT but not
2 F11, could indicate presence of interacting molecules
in the cytoplasm that engage the N-terminal region of
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PTMA therefore masking it from detection by 2 F11. All
together these expression patterns seem to suggest func-
tional differences of PTMA in diverse tissues and cellu-
lar compartments likely associated with different
interacting proteins. Under apoptotic conditions intact
intracellular PTMA can be processed by proteases lead-
ing to different fragments that may differ in biological
functions as showed by PTMA-S100A13 binding studies,
it would therefore be significant to examine subcellular
localization of PTMA under such varying conditions.
Moreover, we cannot rule out possibility of the presence
of PTMA variants with similar N-terminal regions but
differing C-terminal compartments resulting from alter-
native splicing. Further prospective studies are required
to confirm such possible effect.
Conclusion
By analyzing how PTMA is distributed and localized in
tissues and specific cell types under no pathological con-
dition we have triggered prying into its precise role
under such normal conditions given that in some tissues
it was exclusively localized in the cytoplasm while in
other tissues it was present predominantly in the nu-
cleus. This will improve our understanding of mediators
of PTMA biological function during disease. The next
course of action would be to determine the particular
cell types that express PTMA in the tissues that showed
contrasting patterns of PTMA localization like the cells
of the stomach, determine PTMA interacting partners
and explore the biologic consequences of PTMA vari-
ants in same or different cells arising from alternative
splicing.
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